Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Authors

Stephen Salloway

Published

January 22, 2014

Abstract

Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1304839

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Authors

Stephen Salloway

Published

January 22, 2014

Abstract

Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1304839

Paper

Paper

Paper

Paper

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Abstract

Supporters

Journal

Topics

DOI

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Abstract

Supporters

Journal

Topics

DOI